Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2022 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Aclaris Therapeutics, Inc. | 5 | Q4 2017 | 35.0% |
Spark Therapeutics, Inc. | 5 | Q4 2017 | 26.2% |
Natera, Inc. | 5 | Q4 2017 | 12.2% |
Auris Medical Holding AG | 5 | Q4 2017 | 3.9% |
Histogenics Corporation | 5 | Q4 2017 | 2.5% |
ObsEva SA | 4 | Q4 2017 | 25.3% |
Versartis, Inc. | 3 | Q2 2017 | 19.8% |
Mirna Therapeutics, Inc. | 3 | Q2 2017 | 3.4% |
Innocoll Holdings PLC | 3 | Q2 2017 | 2.7% |
NuCana plc | 2 | Q4 2017 | 25.8% |
View Sofinnova Management VIII, L.L.C.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2018-09-20 |
3 | 2018-09-13 |
13F-HR | 2018-02-14 |
13F-HR | 2017-10-11 |
13F-HR | 2017-07-19 |
13F-HR | 2017-04-10 |
13F-HR | 2017-02-14 |
4 | 2015-10-13 |
3 | 2015-10-06 |
4 | 2015-10-06 |
View Sofinnova Management VIII, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.